eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
3/2005
vol. 9
 
Share:
Share:
abstract:

Erytropoetyna, białko von Hippel-Lindau i rak nerki: molekularne podstawy towarzyszącego chorobie nowotworowej zespołu erytrocytozy

Arthur J. Sytkowski

Współcz Onkol (2005) vol. 9; 3 (116–122)
Online publish date: 2005/04/19
View full text Get citation
 
Erythropoietin (Epo) is a glycoprotein hormone that is the principal regulator of red blood cell production. In the adult, it is produced primarily in the kidney in response to hypoxia or reduced hemoglobin. Hypoxic regulation of Epo production is due to activation of the Epo gene by HIF-1 (hypoxia inducible factor-1), a heterodimeric transcription factor comprising HIF-1 a and HIF-1 β subunits. In the presence of oxygen, the HIF-1 α subunit is rapidly proteolysed by a mechanism involving hydroxylation of specific prolyl residues and interaction with von Hippel-Lindau protein (pVHL). In reduced oxygen, HIF-1 α is stabilized, resulting in enhanced gene transcription. The Epo gene is but one of numerous genes, such as the pro-angiogenic VEGF, that are regulated in this manner. The inherited cancer syndrome von Hippel-Lindau disease is characterized by a mutated VHL gene leading to the absence of hypoxic gene regulation. The result is the constitutive expression of normally hypoxically regulated genes, including Epo. Some cases of renal cysts and renal cancer are caused by somatic mutations of the VHL gene in the renal tissue, and these cases often exhibit increased Epo production and the paraneoplastic syndrome of erythrocytosis. Those renal cancers resulting from other mutations but possessing normal VHL genes do not produce Epo. Also, there is heterogeneity of VHL gene deletions within individual renal cell carcinoma tumors, leading to a more complex clinical picture.
keywords:

erythropoietin, von Hippel--Lindau, hypoxia, gene regulation

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.